Inhibrx Biosciences
Logotype for Inhibrx Biosciences Inc

Inhibrx Biosciences (INBX) investor relations material

Inhibrx Biosciences Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Inhibrx Biosciences Inc
Q3 2026 earnings summary13 Nov, 2026

Executive summary

  • Q3 revenue was $2.0M; net loss was $38.7M, or $2.46 per share, and cash and cash equivalents totaled $199.5M at September 30, 2026.

  • Clinical progress included positive Phase 3 chondrosarcoma results, encouraging ordastobart HNSCC Phase 2 data, and FDA review of the ozekibart BLA.

Financial highlights

  • Q3 revenue was $2.0M from a Pfizer license fee versus none in Q3 2025; 9M revenue was $2.0M versus $1.3M in 2025, reflecting Pfizer and Scithera license fees, respectively.

  • Q3 R&D expense fell 9% YoY to $26.0M from $28.5M; G&A rose 47% to $7.8M from $5.3M, primarily due to pre-commercialization and personnel costs.

  • 9M R&D expense declined 14% to $75.1M; G&A increased 23% to $21.7M, driven primarily by pre-commercialization and personnel expenses.

  • Q3 net loss was $38.7M versus $35.3M YoY; 9M net loss was $108.8M versus $107.2M.

  • Q3 operating loss was $31.7M versus $33.8M; 9M interest expense was $18.0M versus $9.0M, reflecting higher debt balances and non-cash debt costs.

Outlook and guidance

  • Cash and cash equivalents are expected to fund operations for at least 12 months from the November 2026 filing; substantial additional capital will be needed for future development and commercialization.

  • R&D expenses are expected to rise as clinical programs advance, particularly in later-stage trials; pre-commercialization and potential launch costs are also expected to increase.

  • Interim results from two additional CRC cohorts are expected in Q1 2027; initial readouts for expanded HPV-positive OPSCC and perioperative NSCLC studies are targeted for mid-2027.

  • Updated Phase 1/2 Ewing sarcoma results were planned for CTOS on Nov. 19–20, 2026; chondrosarcoma commercial readiness and BLA-supporting manufacturing activities are progressing alongside regulatory review.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Inhibrx Biosciences earnings date

Logotype for Inhibrx Biosciences Inc
Q4 202619 Mar, 2027
Inhibrx Biosciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Inhibrx Biosciences earnings date

Logotype for Inhibrx Biosciences Inc
Q4 202619 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Inhibrx Biosciences Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutic candidates. The company's work is centered on leveraging its proprietary protein engineering platforms to design and develop therapies aimed at treating serious and life-threatening conditions. Inhibrx's pipeline includes multiple candidates that target various pathways involved in cancer and other critical diseases, with several programs in clinical trials. Inhibrx Biosciences is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.